Rituximab and Intravenous Immune Globulin for Desensitization during Renal Transplantation
Rituximab and Intravenous Immune Globulin for Desensitization during Renal Transplantation
About this item
Full title
Author / Creator
Publisher
Boston, MA: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
Boston, MA: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
This open-label, phase 1–2, single-center study examined the use of intravenous immune globulin and rituximab to reduce anti-HLA antibodies and improve transplantation rates in 20 highly sensitized patients. Sixteen patients (80%) subsequently received a transplant, and the 1-year survival rates for patients and allografts were 100% and 94%, respec...
Alternative Titles
Full title
Rituximab and Intravenous Immune Globulin for Desensitization during Renal Transplantation
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_69319592
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_69319592
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa0707894
